AiCuris

Executive Summary

AiCuris is a German biopharmaceutical company focused on developing novel antiviral therapies for immunocompromised patients. Its lead program, letermovir (Prevymis), was licensed to Merck and approved for cytomegalovirus prophylaxis. The company is advancing a Phase 3 pipeline, including AIC317 for resistant CMV infections. With expertise in small molecule antivirals, AiCuris addresses growing unmet needs in the immunocompromised population. The company remains privately held, with no disclosed recent funding rounds, but its late-stage assets and established partnerships underpin its value.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line results for AIC317 in resistant CMV60% success
• Q3 2026Potential out-licensing or partnership for early-stage antiviral assets40% success
• Q2 2026Regulatory update from Merck on Prevymis label expansion70% success